$RYTM

4 stories mentioning RYTMUpdated just now

Every FINWIRES story that references RYTM, newest first.

What are analysts saying about RYTM?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on RYTM?

Rhythm Pharmaceuticals Insider Sold Shares Worth $5,133,442, According to a Recent SEC Filing

David P Meeker, Director, President and Chief Executive Officer, on September 14, 2026, sold 50,000 shares in Rhythm Pharmaceuticals (RYTM) for $5,133,442. Following the Form 4 filing with the SEC, Meeker has control over a total of 239,258 common shares of the company, with 239,258 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1649904/000164990426000026/xslF345X05/form4.xml

$RYTM

Research17d ago

Deutsche Bank Initiates Rhythm Pharmaceuticals at Hold With $120 Price Target

Rhythm Pharmaceuticals (RYTM) has an average rating of buy and mean price target of $140.19, according to analysts polled by FactSet.

$RYTM

Insider Trading29d ago

Rhythm Pharmaceuticals Insider Sold Shares Worth $6,620,575, According to a Recent SEC Filing

Yann Mazabraud, Executive Vice President, Head of International, on August 12, 2026, sold 57,000 shares in Rhythm Pharmaceuticals (RYTM) for $6,620,575. Following the Form 4 filing with the SEC, Mazabraud has control over a total of 55,655 common shares of the company, with 55,655 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1649904/000164990426000007/xslF345X05/form4.xml

$RYTM

Research49d ago

JPMorgan Initiates Coverage on Rhythm Pharmaceuticals With Overweight Rating, $145 Price Target

Rhythm Pharmaceuticals (RYTM) has an average rating of Buy and mean price target of $138.80, according to analysts polled by FactSet.

$RYTM

Track with the FINWIRES app suite

FolioX

Track RYTM in your portfolio

WheelAI

Analyze RYTM options with the wheel strategy

StockInsider

See market sentiment on RYTM